Axiom Mission 2
Axiom Space, a private space habitat company, launched its latest mission, Axiom Mission 2 (X-2), to the International Space Station (ISS). The mission aims to conduct experiments on aging, inflammation and cancer of human stem cells in the unique microgravity environment of space. The results of these experiments not only contribute to the participation of astronauts, but also have the potential to advance cancer treatment on Earth.
Microgravity conditions in space have been found to accelerate growth, inflammation and immune dysfunction in human stem cells. A deeper understanding of this process could have significant implications for improving cancer treatment details on Earth.
As part of Ax-2, the Axiom space will investigate whether two inhibitory drugs can reverse regeneration in an organoid model of breast cancer. The aim of this experiment is to shed light on factors that inhibit the growth and progression of cancer cells.
Another set of experiments will monitor the health of the astronauts' blood stem AT before, during and after spaceflight. The research aims to understand the impact of the space environment on stem cell aging, immune communication and the generation of cancer stem cells.
The messages announced by NASA during the X-2 experiment are part of the Center for Space Stem Cell Orbital Research (ISCOR). The collaboration includes the University of California-San Diego Sanford Stem Cell Institute, the JM Foundation, and Axiom Space. The data will be analyzed at UC San Diego during mission consolidation.